QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its variant interpretation and reporting software, QIAGEN Clinical Insight (QCI) In...
SciTech Development today announced it has closed a $2.73M funding round, led by several prominent life science investors to advance clinical trials for No...
Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
Gives Nordic Nanovector access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-b...
CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy. CID can cause dehydration, electrolyte imbalance, m...
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were repor...
Crowell & Moring International is joining forces with Roche, TogetHER for Health, CAPED and Jhpiego to raise awareness about the surge of br...
Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection...
The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515 in solid tumors. Treth...
Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...
Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023...
First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma Iovance Biotherapeutics, Inc. (NASDAQ: IOVA...
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met prima...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
© 2025 Biopharma Boardroom. All Rights Reserved.
